RayKnowChina Research Map
Shortlist

ShenyangChina Medical University (Shenyang)

Liaoning Cancer Hospital & Institute

辽宁省肿瘤医院

Listed for 6 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Liaoning Cancer Hospital & Institute

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌9 papers led
  2. Hepatocellular carcinoma肝细胞癌16 papers led
  3. Stomach cancer胃癌40 papers led2 open trials led
  4. Osteosarcoma骨肉瘤11 papers led
  5. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  6. Takayasu arteritis大动脉炎1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 9 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 2220242025: 442025

2 hospitals in Shenyang for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

  2. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

  3. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  4. Recruiting
    Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06637163

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapyNeoadjuvant & combined treatmentImaging & AI
Departments in papersRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led9
  1. SUMO modified ETV1 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by facilitating CCL2 transcription in esophageal squamous cell carcinoma cells.2025Cancer immunology, immunotherapy : CIIFree full text
  2. Circulating exosome-derived miR-191-5p is a novel therapeutic biomarker for radiotherapy in esophageal squamous cell carcinoma patients.2025Esophagus : official journal of the Japan Esophageal SocietyFree full text
  3. Metabolic state uncovers prognosis insights of esophageal squamous cell carcinoma patients.2025Journal of translational medicineFree full text
  4. Correlation of nutritional support and immunonutritional indicators with prognosis and survival in esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.2025Nutrition journalFree full text
  5. FOXF2 suppressed esophageal squamous cell carcinoma by reducing M2 TAMs via modulating RNF144A-FTO axis.2024International immunopharmacology
  6. Implication of CCNG1 in radiosensitivity via the Wnt/β-catenin pathway in esophageal squamous cells.2024Scientific reportsFree full text
  7. sh-HNF1A-AS1 reduces the epithelial-mesenchymal transition and stemness of esophageal cancer cells.2022Neoplasma
  8. E2F transcription factor 1 is involved in the phenotypic modulation of esophageal squamous cell carcinoma cells via microRNA-375.2021BioengineeredFree full text
  9. A commentary on "A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma" [Int. J. Surg. 80 (2020) 184-191].2021International journal of surgery (London, England)
All its trials on ClinicalTrials.gov, any status13
  1. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  2. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  3. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  4. Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Study sitePhase 2Start 2024-10
  5. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  6. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  7. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  8. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  9. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  10. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  11. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  12. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  13. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)17
  1. 282P Efficacy comparison of immune therapy combined with chemotherapy and radiotherapy versus traditional treatments in locally advanced unresectable esophageal squamous cell carcinoma2025Immuno-Oncology Technologyarticle
  2. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncologyarticle
  3. Multi-Stain Attention Multiple Instance Learning for Prognosis Prediction in Esophageal Squamous Cell Carcinoma2025IEEE International Conference on Bioinformatics and Biomedicine (BIBM)conference-paper
  4. The Tumor-Promoting Role of Neutrophil Extracellular Traps in Esophageal Squamous Cell Carcinoma and Their Interaction with the Gut Microbiota2025Research Squarepreprint
  5. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technologyarticle
  6. Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow2024Journal of Clinical Oncologyconference-abstract
  7. 1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell 2023Annals of Oncologyarticle
  8. 1514P Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update2023Annals of Oncologyarticle
  9. Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis2023Cancer Researchconference-abstract
  10. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  11. Safety and feasibility of neoadjuvant immunotherapy combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma2023Research Squarepreprint
  12. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncologyconference-abstract
  13. 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup2022Annals of Oncologyarticle
  14. A randomized, controlled, multicenter study of nab-paclitaxel plus cisplatin followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma (ESCC).2022Journal of Clinical Oncologyconference-abstract
  15. Distinct landscapes of genetic and epigenetic alterations of E2F familygenes between esophageal squamous cell carcinoma and esophageal adenocarcinoma2022Research Squarepreprint
  16. LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)2022Annals of Oncologyarticle
  17. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas2021Annals of Oncologyarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 16 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 4420212022: 4420222023: 3320232024: 0020242025: 552025

4 hospitals in Shenyang for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou

  2. Recruiting
    Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06940102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  3. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  4. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  5. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  6. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  7. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatology
Papers it led16
  1. Transcriptional regulation of ATOX1 by PRRX2 impacts the progression and cuproptosis of hepatocellular carcinoma.2025Cellular signalling
  2. The multifaceted role of microbiota in liver cancer: pathogenesis, therapy, prognosis, and immunotherapy.2025Frontiers in immunologyFree full text
  3. Nanomaterials for liver cancer targeting: research progress and future prospects.2025Frontiers in immunologyFree full text
  4. Consensus Integration of Multiomics Data With Machine Learning Algorithms Reveals Heterogeneous Molecular Subtypes and Enables Personalized Treatment Strategies for Hepatocellular Carcinoma.2025Human mutationFree full text
  5. Interpretable machine learning model for predicting post-hepatectomy liver failure in hepatocellular carcinoma.2025Scientific reportsFree full text
  6. A novel nomogram for predicting microvascular invasion in hepatocellular carcinoma.2023Annals of hepatology
  7. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized co2023BMC cancerFree full text
  8. The predictive value of the preoperative albumin-to-fibrinogen ratio for postoperative hospital length of stay in liver cancer patients.2023Cancer medicineFree full text
  9. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating Reelin gene expression.2022BioengineeredFree full text
  10. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.2022Computational and mathematical methods in medicineFree full text
  11. Preoperative tumor abnormal protein is a promising biomarker for predicting hepatocellular carcinoma oncological outcome following curative resection.2022Journal of cancer research and therapeutics
  12. Early assessment of chemotherapeutic response in hepatocellular carcinoma based on serum surface-enhanced Raman spectroscopy.2022Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  13. USP14 maintains HIF1-α stabilization via its deubiquitination activity in hepatocellular carcinoma.2021Cell death & diseaseFree full text
  14. Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis.2021Digestive diseases and sciences
  15. Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α.2021Drug deliveryFree full text
  16. Novel small molecular inhibitor of Pit-Oct-Unc transcription factor 1 suppresses hepatocellular carcinoma cell proliferation.2021Life sciences
All its trials on ClinicalTrials.gov, any status12
  1. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  2. Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive TumorsRecruitingNCT06940102Study siteStart 2025-03
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  5. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  6. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  7. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  8. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Study sitePhase 1Start 2024-09
  9. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  10. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  11. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  12. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 40 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
40
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 9920212022: 8820222023: 4420232024: 5520242025: 12122025

4 hospitals in Shenyang for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07311408

    Age 18 years to Not stated (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  2. Recruiting
    Two-component Radiology-guided Autonomous Cascade Engine (TRACE)
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07651644

    Age not stated (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  3. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  4. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  5. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  6. Recruiting
    Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06940102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  7. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  8. Recruiting
    A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06783569

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang

  9. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseChemotherapy & combined treatmentImmunotherapy & targeted drugs
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology
Papers it led40
  1. PGM5 - AS1 regulates ferroptosis - Mediated gastric cancer cell behavior via ERK signaling pathway.2026Cellular signalling
  2. Multicenter research: tumor microenvironment features combined with tumor cell characteristics predict lymph node metastasis in early gastric cancer.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  3. A systematic review and meta-analysis of incidence trends and risk factors for metachronous gastric lesions following endoscopic resection.2025Annals of medicineFree full text
  4. Tumor immune microenvironment remodeling after neoadjuvant therapy in gastric cancer: Update and new challenges.2025Biochimica et biophysica acta. Reviews on cancer
  5. Interpretable combined models for predicting treatment response and hematologic toxicity in locally advanced gastric cancer treated with PD-1 blockade and neoadjuvant chemotherapy.2025European journal of radiology
  6. Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case.2025Frontiers in immunologyFree full text
  7. Harnessing glycolysis in gastric cancer: molecular targets, therapeutic strategies, and clinical horizons.2025Frontiers in immunologyFree full text
  8. Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial.2025Frontiers in immunologyFree full text
  9. Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives.2025Frontiers in immunologyFree full text
  10. Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer.2025Frontiers in immunologyFree full text
  11. Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.2025Future oncology (London, England)Free full text
  12. Global trends and risk factors in gastric cancer: a comprehensive analysis of the Global Burden of Disease Study 2021 and multi-omics data.2025International journal of medical sciencesFree full text
  13. Potential Value of AURKA and CDK6 Amplification for the Response of Patients With Gastric Cancer to Neoadjuvant Chemotherapy.2025Molecular carcinogenesis
  14. CYP19A1 Silencing Inhibits Cell Proliferation and Endoplasmic Reticulum Stress in Stomach Adenocarcinoma.2025Oncology researchFree full text
  15. Role of pathological tumor regression grade of lymph node metastasis following neoadjuvant chemotherapy in locally advanced gastric cancer.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  16. Intratumoral and fecal microbiota reveals microbial markers associated with gastric carcinogenesis.2024Frontiers in cellular and infection microbiologyFree full text
  17. Exosome-mediated communication between gastric cancer cells and macrophages: implications for tumor microenvironment.2024Frontiers in immunologyFree full text
  18. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled t2024International immunopharmacology
  19. Primary malignant melanoma of the gastroesophageal junction with KIT gene exon 11 mutation.2024JPMA. The Journal of the Pakistan Medical Association
  20. FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer.2023BMC cancerFree full text
  21. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.2023International immunopharmacology
  22. GATA6-AS1 via Sponging miR-543 to Regulate PTEN/AKT Signaling Axis Suppresses Cell Proliferation and Migration in Gastric Cancer.2023Mediators of inflammationFree full text
  23. Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology.2023Seminars in cancer biology
  24. LMOD1, an oncogene associated with Lauren classification, regulates the metastasis of gastric cancer cells through the FAK-AKT/mTOR pathway.2022BMC cancerFree full text
  25. Long-term outcomes and clinical safety of expanded indication early gastric cancer treated with endoscopic submucosal dissection versus surgical resection: a meta-analysis.2022BMJ openFree full text
  26. Lemur tyrosine kinase 2 silencing inhibits the proliferation of gastric cancer cells by regulating GSK-3β phosphorylation and β-catenin nuclear translocation.2022BioengineeredFree full text
  27. D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer.2022Chinese medical journalFree full text
  28. Cytokine-driven positive feedback loop organizes fibroblast transformation and facilitates gastric cancer progression.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  29. Hypoxia associated lncRNA HYPAL promotes proliferation of gastric cancer as ceRNA by sponging miR-431-5p to upregulate CDK14.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  30. A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression.2022Journal of experimental & clinical cancer research : CRFree full text
  31. Effects of probiotics on gastric cancer-related inflammation: A systematic review and meta-analysis.2022Journal of food biochemistry
  32. The assessment of the optimal number of examined lymph nodes and prognostic models based on lymph nodes for predicting survival outcome in patients with stage N3b gastric cancer.2021Asia-Pacific journal of clinical oncology
  33. CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.2021BMC cancerFree full text
  34. Evaluation and Comparison of Predictive Value of Tumor Regression Grades according to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma.2021Cancer research and treatmentFree full text
  35. Exosome-transmitted lncRNA PCGEM1 promotes invasive and metastasis in gastric cancer by maintaining the stability of SNAI1.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  36. Totally Laparoscopic Gastrectomy Versus Laparoscopic-Assisted Gastrectomy for Gastric Cancer: A Systematic Review and Meta-Analysis.2021Journal of laparoendoscopic & advanced surgical techniques. Part A
  37. Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  38. Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer.2021Translational research : the journal of laboratory and clinical medicine
  39. Surgical resection of esophagogastric junction stromal tumor: How to protect the cardiac function.2021World journal of gastroenterologyFree full text
  40. Application of Computed Tomography Images Based on Peripheral Nerve Analysis in the Treatment of Gastric Scrotal Tumors.2021World neurosurgery
Chinese-language papers (not in the count)1
  1. [Clinicopathological factors and clinical significance of No.12b lymph node metastasis in gastric antrum cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status32
  1. Two-component Radiology-guided Autonomous Cascade Engine (TRACE)RecruitingNCT07651644Lead sponsorN/AStart 2026-06
  2. SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy FailureRecruitingNCT07311408Lead (inferred)Phase 2Start 2026-01
  3. PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric AdenocarcinomaStatus unknownNCT04006821Lead (inferred)Phase 2Start 2019-07
  4. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  5. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  6. Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive TumorsRecruitingNCT06940102Study siteStart 2025-03
  7. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  8. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  9. A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid TumorsRecruitingNCT06783569Study sitePhase 1Start 2024-12
  10. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  11. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingNCT06116136Study sitePhase 1/Phase 2Start 2024-08
  12. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaCompletedNCT06585501Study siteStart 2024-08
  13. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  14. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  15. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  16. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  17. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  18. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Study sitePhase 2Start 2021-08
  19. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Study sitePhase 3Start 2021-05
  20. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  21. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  22. Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabCompletedNCT04276493Study sitePhase 1/Phase 2Start 2020-03
  23. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  24. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  25. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  26. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  27. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  28. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  29. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  30. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Study sitePhase 3Start 2018-01
  31. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Study sitePhase 2Start 2018-07
  32. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 11 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 1120222023: 0020232024: 0020242025: 332025

7 hospitals in Shenyang for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led11
  1. Multimodal therapy process engineering mediated by 3D-printed scaffolds for enhanced postoperative osteosarcoma regeneration.2026Tissue & cell
  2. Prediction of High-Dose Methotrexate Blood Concentration in Osteosarcoma Patients Using Machine Learning.2025Drug design, development and therapy
  3. Glypican-3 regulated epithelial mesenchymal transformation-related genes in osteosarcoma: based on comprehensive tumor microenvironment profiling.2025Frontiers in immunology
  4. Unraveling the impact of noncoding RNAs in osteosarcoma drug resistance: a review of mechanisms and therapeutic implications.2025International journal of surgery (London, England)
  5. Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma.2022Frontiers in immunology
  6. PTHR1 in osteosarcoma: Specific molecular mechanisms and comprehensive functional perspective.2021Journal of cellular and molecular medicine
  7. Parathyroid hormone type 1 receptor regulates osteosarcoma K7M2 Cell growth by interacting with angiotensinogen.2021Journal of cellular and molecular medicine
  8. The potential roles of exosomal noncoding RNAs in osteosarcoma.2021Journal of cellular physiology
  9. The basic characteristics of extracellular vesicles and their potential application in bone sarcomas.2021Journal of nanobiotechnology
  10. CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis.2021Molecular cancer
  11. Establishment and validation of prognostic nomograms to predict overall survival and cancer-specific survival for patients with osteosarcoma.2021NeoplasmaRCT
Chinese-language papers (not in the count)1
  1. [The clinical predictors for the prognosis of patients with osteosarcoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
Earlier papers (2016–2020)17
  1. Extracellular nanovesicles-transmitted circular RNA has_circ_0000190 suppresses osteosarcoma progression.2020Journal of cellular and molecular medicine
  2. Magnoflorine inhibits the malignant phenotypes and increases cisplatin sensitivity of osteosarcoma cells via regulating miR-410-3p/HMGB1/NF-κB pathway.2020Life sciences
  3. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.2020World journal of surgical oncology
  4. Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p.2019Aging
  5. Long noncoding RNA TTN-AS1 enhances the malignant characteristics of osteosarcoma by acting as a competing endogenous RNA on microRNA-376a thereby upregulating dickkopf-1.2019Aging
  6. Quercetin suppresses the proliferation and metastasis of metastatic osteosarcoma cells by inhibiting parathyroid hormone receptor 1.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. Circular RNA 0001785 regulates the pathogenesis of osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2.2019Cell cycle (Georgetown, Tex.)
  8. PTHR1 May Be Involved in Progression of Osteosarcoma by Regulating miR-124-3p-AR-Tgfb1i1, miR-27a-3p-PPARG-Abca1, and miR-103/590-3p-AXIN2 Axes.2019DNA and cell biology
  9. Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial.2019Medical science monitor : international medical journal of experimental and clinical researchRCT
  10. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].2019Zhonghua zhong liu za zhi [Chinese journal of oncology]
  11. Long noncoding RNA MALAT1 regulates HDAC4-mediated proliferation and apoptosis via decoying of miR-140-5p in osteosarcoma cells.2018Cancer medicine
  12. β-Alanine mediated inhibition of PTHR1suppresses the proliferation, invasion and tumorigenesis in metastatic human osteosarcoma U2OS cells.2018International journal of biological macromolecules
  13. Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells.2018Oncology reports
  14. Histone Demethylase JARID1B Is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression via Demethylation of H3K27me3.2018Oncology research
  15. SPOCK1 promotes the growth of Osteosarcoma cells through mTOR-S6K signaling pathway.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  16. Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcoma.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  17. Transcriptomic analyses reveal the underlying pro-malignant functions of PTHR1 for osteosarcoma via activation of Wnt and angiogenesis pathways.2017Journal of orthopaedic surgery and research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Shenyang for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shenyang for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

辽宁省肿瘤医院

Liaoning Cancer Hospital & Institute

沈阳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Cancer Hospital of China Medical University; Liaoning Cancer Hospital & Institute; Liaoning Cancer Hospital and Institute; Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital; Cancer Hospital of China Medical University/Liaoning Cancer Hospital; Liaoning Cancer Hospital and Institution; Liaoning Cancer Hospital & Insititute

Suggest a correctionDownload the data